A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
Latest Information Update: 07 Aug 2023
At a glance
- Drugs PCS 499 (Primary)
- Indications Necrobiosis lipoidica; Ulcer
- Focus Therapeutic Use
- Sponsors Processa Pharmaceuticals
- 24 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 15 Aug 2022 Planned primary completion date changed from 1 Aug 2022 to 31 Mar 2023.